Clinical Cancer Research, Vol 4, Issue 2 411-418, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Assessment of messenger RNA of beta 1-->4-N-acetylgalactosaminyl-transferase as a molecular marker for metastatic melanoma

CT Kuo, PJ Bostick, RF Irie, DL Morton, AJ Conrad and DS Hoon
Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA.

Gangliosides GM2 [GalNAc beta 1-4(NeuAc alpha 2-3)Gal beta 1-4Glc beta 1-1Cer] and GD2 [GalNAc beta 1-4(NeuAc alpha 2-8NeuAc alpha 2-3)Gal beta 1-4Glc beta 1-1Cer] are cell surface tumor-associated antigens and have been demonstrated to be important markers of human malignant melanoma progression. Expression of these glycolipid antigens on melanoma tissues can be assessed by immunohistochemistry or biochemical analysis. These methodologies, however, are not logistically practical or sensitive for testing metastatic melanoma cells in blood or in tissue biopsies. In the present study, we hypothesized that the enzyme involved in GM2 and GD2 synthesis, beta 1-->4-N-acetylgalactosaminyltransferase (beta 1-->4GalNac-T), can be a useful marker for detection of occult metastatic melanoma. A reverse transcription PCR and Southern blot assay to detect beta 1-->4GalNac-T mRNA expression was developed. Beta 1-->4GalNac-T mRNA was detected in all 13 melanoma cell lines tested. Metastatic melanoma of lymph nodes and different organ sites expressed beta 1-->4GalNac-T mRNA at various levels. Detection sensitivity of the reverse transcription PCR assay was 1 ng of total RNA extracted from tumor specimens and approximately 5 melanoma cells in 20 million normal donor peripheral blood lymphocytes. In assessment of blood from 126 melanoma patients, beta 1-->4GalNac-T mRNA was more frequently found in advanced-stage melanomas and in patients showing more aggressive tumor progression. Normal donor blood samples (n = 37) were all negative for beta 1-->4GalNac-T mRNA expression. These results suggest that beta 1-->4GalNac-T mRNA is a promising molecular marker for detecting melanoma cells, characterizing antigen expression, and monitoring tumor progression.

This article has been cited by other articles:

				S. Mocellin, D. Hoon, A. Ambrosi, D. Nitti, and C. R. Rossi The Prognostic Value of Circulating Tumor Cells in Patients with Melanoma: A Systematic Review and Meta-analysis Clin. Cancer Res., August 1, 2006; 12(15): 4605 - 4613. [Abstract] [Full Text] [PDF]

				K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, H.-J. Wang, R. M. Elashoff, H. Takeuchi, N. Umetani, et al. Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial J. Clin. Oncol., November 1, 2005; 23(31): 8057 - 8064. [Abstract] [Full Text] [PDF]

				K. Koyanagi, C. Kuo, T. Nakagawa, T. Mori, H. Ueno, A. R. Lorico Jr, H.-J. Wang, E. Hseuh, S. J. O'Day, and D. S.B. Hoon Multimarker Quantitative Real-Time PCR Detection of Circulating Melanoma Cells in Peripheral Blood: Relation to Disease Stage in Melanoma Patients Clin. Chem., June 1, 2005; 51(6): 981 - 988. [Abstract] [Full Text] [PDF]

				H. Takeuchi, D. L. Morton, C. Kuo, R. R. Turner, D. Elashoff, R. Elashoff, B. Taback, A. Fujimoto, and D. S.B. Hoon Prognostic Significance of Molecular Upstaging of Paraffin-Embedded Sentinel Lymph Nodes in Melanoma Patients J. Clin. Oncol., July 1, 2004; 22(13): 2671 - 2680. [Abstract] [Full Text] [PDF]

				R. Peracaula, G. Tabares, L. Royle, D. J. Harvey, R. A. Dwek, P. M. Rudd, and R. de Llorens Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins Glycobiology, June 1, 2003; 13(6): 457 - 470. [Abstract] [Full Text] [PDF]

				R. Peracaula, L. Royle, G. Tabares, G. Mallorqui-Fernandez, S. Barrabes, D. J. Harvey, R. A. Dwek, P. M. Rudd, and R. de Llorens Glycosylation of human pancreatic ribonuclease: differences between normal and tumor states Glycobiology, April 1, 2003; 13(4): 227 - 244. [Abstract] [Full Text] [PDF]

				B. Taback, A. D. Chan, C. T. Kuo, P. J. Bostick, H.-J. Wang, A. E. Giuliano, and D. S. B. Hoon Detection of Occult Metastatic Breast Cancer Cells in Blood by a Multimolecular Marker Assay: Correlation with Clinical Stage of Disease Cancer Res., December 1, 2001; 61(24): 8845 - 8850. [Abstract] [Full Text] [PDF]

				D. S. B. Hoon, C. T. Kuo, S. Wen, H. Wang, L. Metelitsa, C. P. Reynolds, and R. C. Seeger Ganglioside GM2/GD2 Synthetase mRNA Is a Marker for Detection of Infrequent Neuroblastoma Cells in Bone Marrow Am. J. Pathol., August 1, 2001; 159(2): 493 - 500. [Abstract] [Full Text]

				I. Y. Cheung and N.-K. V. Cheung Quantitation of Marrow Disease in Neuroblastoma by Real-Time Reverse Transcription-PCR Clin. Cancer Res., June 1, 2001; 7(6): 1698 - 1705. [Abstract] [Full Text] [PDF]

				D. S. B. Hoon, P. Bostick, C. Kuo, T. Okamoto, H.-J. Wang, R. Elashoff, and D. L. Morton Molecular Markers in Blood as Surrogate Prognostic Indicators of Melanoma Recurrence Cancer Res., April 1, 2000; 60(8): 2253 - 2257. [Abstract] [Full Text]

				P. J. Bostick, D. L. Morton, R. R. Turner, K. T. Huynh, H.-J. Wang, R. Elashoff, R. Essner, and D. S.B. Hoon Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse Transcriptase–Polymerase Chain Reaction in Early-Stage Melanoma Patients J. Clin. Oncol., October 1, 1999; 17(10): 3238 - 3244. [Abstract] [Full Text] [PDF]

				I. Y. Cheung, N.-K. V. Cheung, R. A. Ghossein, J. M. Satagopan, S. Bhattacharya, and D. G. Coit Association between Molecular Detection of GAGE and Survival in Patients with Malignant Melanoma: A Retrospective Cohort Study Clin. Cancer Res., August 1, 1999; 5(8): 2042 - 2047. [Abstract] [Full Text] [PDF]